AF
LENZ

Amalgamated Financial’s LENZ Therapeutics LENZ Stock Holding History

Amalgamated Financial’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$21K Buy
+597
New +$37.3K ﹤0.01% 2741

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Amalgamated Financial's LENZ Position: Q1 2022 in Review

Amalgamated Financial opened a new position in LENZ Therapeutics (LENZ) in Q1 2022: 597 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #2741 among its holdings.

63 funds tracked by Wall St. Rank hold LENZ as of Q1 2022.

  • Amalgamated Financial held 597 shares of LENZ Therapeutics worth $21K as of Q1 2022.
  • LENZ Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • LENZ Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2741 holding.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.